Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma
- Conditions
- Hodgkin Disease
- Registration Number
- NCT00148018
- Lead Sponsor
- University of Cologne
- Brief Summary
The primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed Hodgkin's lymphoma.
- Detailed Description
The proteasome-inhibitor bortezomib (Velcade) shows promising activity in various human lymphoma cell line. In addition, several studies in heavily pretreated patients with lymphoma showed also promising results.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 37
- Hodgkin's lymphoma
- Second or higher relapse (first relapse if high-dose chemotherapy not possible)
- Age >/= 18 years
- No major organ dysfunction or intercurrent disorder
- Written informed consent
- Pregnant or nursing
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Overall response rate (complete and partial responses)
- Secondary Outcome Measures
Name Time Method Toxicity Event free survival Overall survival Duration of response Treatment administration (dose-intensity, total dose)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
University of Cologne
🇩🇪Cologne, NRW, Germany
University of Cologne🇩🇪Cologne, NRW, Germany